Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF-Mutant Melanoma.

Kyoo Hyun KimSungmin ChoYeyeong JeongEun Sil BaekChung LeeHyang-Joo RyuYoung Su NohYoon-Hee HongKee Yang ChungMi Ryung RohByung Ho OhChang Gon KimMinkyu JungSang Joon Shin

Published in: The oncologist (2024)

Our study highlights the value of NGS in detecting BRAF, NRAS mutations and RAF fusions, expanding possibilities for targeted therapies in malignant melanoma. Belvarafenib showed clinical benefit in patients harboring these alterations. Ongoing trials will provide further insights into the safety and efficacy of belvarafenib.

Keyphrases

wild type
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
gene expression
skin cancer
dna methylation
single molecule
patient reported